KEEGO HARBOR, MI--(Marketwired - December 21, 2015) - ZIVO Bioscience, Inc. (OTCQB: ZIVO), announces today that its wholly-owned subsidiary, WellMetris LLC, has successfully concluded manufacturing runs of assays for its proprietary, patent-pending metabolic testing panel for human application. The manufacturing run completes the full wellness panel with the latest assay formulations.
The WellMetris pre-clinical health and wellness screening platform derives its biomarker data from a proprietary panel of eight (8) chemical assays which are, in this specific instance, activated by human urine. The assays are analyzed by a proprietary device developed by WellMetris and then ported to a PC, laptop, tablet or smartphone to display test data. The results of the wellness panel provide unprecedented insight into human wellness and pre-conditions favorable to the onset of disease, such as CVD, stroke, diabetes and cancer.
With that information in hand, wellness consultants, early intervention practitioners, health agencies, insurers and employers can help shape an appropriate response, offering alternatives to unhealthy lifestyle choices. The company will also field a consumer version of the test panel for in-home use, again providing a unique insight into the effects of diet, sleep, exercise, hydration and vitamins on overall health and vitality.
The production run, concluded over the previous weekend, includes unique dry chemistries for oxidative stress, inflammation and antioxidant biomarkers, which has also resulted in additional provisional patent filings to protect novel formulae and production techniques.
With the components to make roughly 5,000 individual tests on hand, WellMetris scientists will first conduct lab testing to make sure there is consistency in the test chemistry results and the analyzer device before commencing human norming. The pace of the WellMetris development program had been slowed somewhat by available funding, but forward momentum continues to yield progress toward product launch.
“We’re especially happy with the progress we’ve made on a wide-ranging and quite sensitive measure of systemic inflammation,” states Director of Engineering Kerry Wilson. “We think we’ve cracked the code on measuring fairly low levels of chronic, largely undetectable forms of inflammation that over time can really become a problem for otherwise asymptomatic individuals.”
Chief Medical Officer Dr. Scott Freeman concurs.
“We need to put a tool in the hands of wellness consultants, early intervention practitioners and preventive medicine professionals that will help them identify individuals at special risk from unhealthy lifestyle choices before they get sick,” says Dr. Freeman. “The healthcare delivery system in this country is predominantly reactive. We need to get ahead of the curve by identifying unhealthy bodily processes well in advance of frank disease or conditions like Metabolic Syndrome. That’s when changes in diet and activity will likely have the most beneficial and pronounced effect at the lowest cost to the payer and individual.”
The Company expects to announce further progress toward product launch in the coming weeks, as it continues development of test kit packaging and biohazard mitigation in parallel with assay-related development activities.
About WellMetris, LLC
WellMetris, LLC, a wholly-owned subsidiary of ZIVO Bioscience, Inc. develops and markets metabolic testing technologies for humans and animals -- a biomed/IT convergence platform based on its proprietary chemistry, software and cloud-based data warehousing. The Company is currently positioning its first product for market introduction.
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company’s ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
